Ekta Batra

Prerna Jhunjhunwala, Vice President Equity Research at Elara Capital, said the India-UK Free Trade Agreement removes a key disadvantage for Indian textile exporters by eliminating import tariffs. She expects companies with existing UK exposure, including SP Apparels, KPR Mill, Wellspun Living and Indo Count, to benefit. Elara Capital also sees Arvind Ltd as a top pick, citing growth opportunities in technical textiles and expanding garment exports.

Dr. Reddy's Bachupally unit has two blocks, one is an older block, from which the biosimilar Rituximab was filed, and the other one is for the biosimilar abatacept. Nomura believes that most of the observations are for the new unit and issues at the old one are likely to have been addressed.

Shares of Dr. Reddy's Laboratories are trading 4.6% higher on Monday at ₹1,413.1. The stock has gained 8.5% so far in the month of June, which has turned out to be its best month since December 2024, during which it had gained 15%.

Sudesh Sharma, Chief Financial Officer of Park Medi World, said the company will commission Park Hospital Platinum, a 100-bed extension of its existing 225-bed Palam Vihar hospital in Gurugram, in November 2026. The project will be developed with an investment of ₹25 crore.

Amit Anwani, Research Analyst at PL Capital Group, expects a defence and commercial shipbuilding pipeline exceeding ₹2 lakh crore to support growth, while Bharat Electronics remains his preferred stock under coverage, with Solar Industries also offering long-term opportunities.

Nalinikanth Gollagunta, CEO-Automotive Division of Mahindra & Mahindra and ED of Mahindra Electric Automobile said that supply chain issues have eased, sports utility vehicle (SUV) demand remains robust, and Mahindra expects monthly electric vehicle (EV) sales to stay in the 7,000-8,000 range this fiscal, supported by new launches and favourable government policies.

Prashant Mathur, CEO of Saatvik Green Energy explains why cell manufacturing will become the key differentiator under Approved List of Models and Manufacturers (ALMM) list-II, outlines the company's multi-phase expansion plans, funding strategy, 2026-27 (FY27) revenue outlook of around ₹6,000 crore and expects earnings before interest, taxes, depreciation and amortisation (EBITDA) margins to remain broadly stable.

Sandip Agarwal, Fund Manager at Sowilo Investment Managers, said India's IT sector is nearing a turning point after a prolonged valuation correction. He expects earnings stability by the September quarter and believes enterprise AI will drive upgrades, re-rating and buying interest from the next quarter or over the next six months. Agarwal prefers traditional IT services over ER&D companies, citing valuation concerns and AI-led disruption in the latter.

Macquarie's Kunal Dhamesha expects currency depreciation to offset part of the earnings drag from the absence of key generic products this quarter. He remains cautious on Dr. Reddy's semaglutide opportunity in Canada, sees Biocon benefiting from a stronger biologics pipeline, expects US generic price erosion to remain in the mid-single digits, and believes semaglutide will become a meaningful growth driver over the next three to five years.

Chandra Kishore Thakur, Global CEO of Sterling and Wilson Renewable Energy, said the company is targeting around 15% revenue growth, 8-10% margins and order inflows above ₹10,000 crore. The company also expects international projects, including its Egypt order, to contribute higher-margin revenue.